PPCB: financial statements from SEC — TradeAlmanac

PPCB

Propanc Biopharma, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024
Research and development	169,660	19,961	60,201	54,097	54,388	61,714
Selling, general and administrative	6m	4m	5m	53m	153,593	220,759
Operating expenses	6m	4m	5m	53m	213,382	290,790
Operating income	−6m	−4m	−5m	−53m	−213,382	−290,790
Pre-tax income	−6m	−3m	−5m	−54m	−430,183	−354,310
Net income	−6m	−3m	−5m	−54m	−430,183	−354,310
Earnings per share	−0.28	−0.30	−0.39	−12.50	−32.23	−35.97
Earnings per share, diluted	−0.28	−0.30	−0.39	−12.50	−32.23	−35.97
Weighted average shares	22m	13m	12m	4m	13,347	9,849
Weighted average shares, diluted	22m	13m	12m	4m	13,347	9,849

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Current assets	8m	8m	9m	8m	10m	17,984	21,534	25,441
Property, plant and equipment	4,221	4,397

Cash flow

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Mar 31, 2025	Sep 30, 2024
Operating cash flow	—	—	−2m	—	−235,515
Depreciation and amortisation	316	229	125	0	—
Share-based compensation

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)